Exchange: NASDAQ·Updated 05:14 PM EDT
News
all
press releases
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting...
Yahoo! Finance: News
More News
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Key PointsDavid Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026...
Nasdaq News: Markets
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are presently covering the stock...
MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 8.3% - What's Next...
MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen raised shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 10.2% - What's Next...
MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5% - What's Next?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 9.5% Higher - Here's What Happened...
MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group raised shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Friday...
MarketBeat
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
Goldman Sachs initiated coverage of Corvus with a ‘Buy’ rating and $40 price target, according to The Fly.
Stocktwits

Advertisement|Remove ads.